XAV-939

Catalog No.S1180

XAV-939 selectively inhibits Wnt/β-catenin-mediated transcription through tankyrase1/2 inhibition with IC50 of 11 nM/4 nM in cell-free assays, regulates axin levels and does not affect CRE, NF-κB or TGF-β.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 170 In stock
USD 270 In stock
USD 770 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

XAV-939 Chemical Structure

XAV-939 Chemical Structure
Molecular Weight: 312.31

Validation & Quality Control

Customer Product Validation(5)

Quality Control & MSDS

Related Compound Libraries

Product Information

  • Compare Wnt/beta-catenin Inhibitors
    Compare Wnt/beta-catenin Products
  • Research Area
  • XAV-939 Mechanism

Product Description

Biological Activity

Description XAV-939 selectively inhibits Wnt/β-catenin-mediated transcription through tankyrase1/2 inhibition with IC50 of 11 nM/4 nM in cell-free assays, regulates axin levels and does not affect CRE, NF-κB or TGF-β.
Targets TNKS2 [1]
(Cell-free assay)
TNKS1 [1]
(Cell-free assay)
IC50 4 nM 11 nM
In vitro XAV-939 specifically inhibits tankyrase PARP activity. XAV-939 dramatically decreases DNA-PKcs protein levels, confirming the critical role of tankyrase poly-ADP-ribosylation activity in maintaining stability of the DNA-PKcs protein. The greatest reduction of DNA-PKcs protein levels (< 25% relative expression compared to DMSO treated controls) occurs at 12 hours with 1.0 μM XAV-939 exposure. Treatment of human lymphoblasts with 1.0 μM XAV-939 results in marked elevation of tankyrase 1 levels. [1] XAV-939 is axin stabilizing agent. XAV-939 stimulates beta-catenin degradation by stabilizing axin, the concentration-limiting component of the destruction complex. XAV-939 stabilizes axin by blocking the poly-ADP-ribosylating enzymes tankyrase 1 and tankyrase 2. Both tankyrase isoforms interact with a highly conserved domain of axin and stimulate its degradation through the ubiquitin-proteasome pathway. XAV-939 deregulates the Wnt/b-catenin pathway which has been implicated in many cancers. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
Sf-21NEDodFZMcW6jc3WgRZN{[Xl?MmDtNVgvPzVizszNMor1OlAhdWmwMWPEUXNQNWrtTYpOUW6qaXLpeIlwdiCxZjDOMZRmem2rbnHsJGdUXC22YXfn[YQhXE6NU{Kg[ZhxemW|c3XkJJdqfGhiSVO1NEBw\iByLkCwOVMh|ryPNUDVR2N6OjN6N{m0N|E>
HEK293TMkW3SpVv[3Srb36gRZN{[Xl?NGfLU|BFVVORMVXJcohq[mm2aX;uJI9nKFewdDDzbYdv[WyrbnegZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDmc5J{c2:uaX6tbY5lfWOnZDDjRW1RKHKnc4DvcpNmKGWuZX3lcpQh[WO2aY\heIlwdiC5aYToJGlEPTBib3[gNE4xPzhizszNM{TFS|I{QDd7NEOx
HEK293TNVX2OmRsTnWwY4Tpc44hSXO|YYm=NV7WOHNrOTBizszNNGS1eVhFVVORNYPZcplVUW6qaXLpeIlwdiCxZjDi[ZRiNWOjc3Xpck1l\XCnbnTlcpQh[2Gwb37pZ4FtKFewdEOgdIF1cHejeTD3bZRpKEmFNUCgc4YhOC5yNUGg{txONWLs[VE{OjJzOUG1OVc>
HEK293TM1TPcmZ2dmO2aX;uJGF{e2G7NUn0Xlh4OjRiaB?=NH;hUHdFVVORM33mRmlvcGmkaYTpc44hd2ZibX;1d4UhX262M1Ggd4lodmGuaX7nJJdqfGhiSVO1NEBw\iByLkC3PEDPxE1?NYjrSmRyOjJ{NkCyNFM>
SW480MorZSpVv[3Srb36gRZN{[Xl?NEnEdIkyOCEQvF2=MlPINlQhcA>?MVnEUXNQM3LhcnN1[WKrbHn6ZZRqd25ib3[gRZhqdjJid3n0bEBGSzVyIH;mJFAvOzdzIN88US=>M{fkNFIzOjZyMkCz
HEK293TM{\FRmZ2dmO2aX;uJGF{e2G7M4OxPFUxKM7:TR?=NXvKb5lOTE2VTx?=M1WwdmhieyCwbzDF[oZm[3Rib36g[o9ze2uxbHnuMYlv\HWlZXSgZ2FOWCC|aXfuZYxqdmdiaX6gbJVu[W5iSFXLNlk{XCClZXzsd{Bkd2W6cILld5NqdmdiQ2LFMnTjNlIzPjB{MEO=
IEC-6MoDVSpVv[3Srb36gRZN{[Xl?NVOzboJSPiCqM4W0TGFvfGGpb37pd5Qh[WO2aY\peJkh[XRiQnX0ZU1k[XSnbnnuM3RETiCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFewdD2zZU1qdmS3Y3XkJIF5cW5{IHX4dJJme3Orb36ge4l1cCCLQ{WwJI9nKDBwNkSg{txONH;uXXEzPDB4MES4PS=>
IEC-6MX\GeY5kfGmxbjDBd5NigQ>?NWT2eJVuPiCqM1X6Z2FvfGGpb37pd5Qh[WO2aY\peJkh[XRiQnX0ZU1k[XSnbnnuM3RETiCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFewdD2zZU1qdmS3Y3XkJIxoejViZYjwdoV{e2mxbjD3bZRpKEmFNUCgc4YhOi57IN88US=>MoXONlQxPjB2OEm=
DLD1NV[wcnJHTnWwY4Tpc44hSXO|YYm=M{PGSlIxKM7:TR?=MlzVNlQhcA>?NInl[WFFVVORM365eGlvcGmkaYTpc44hd2ZidHHub5lz[XOnIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiVFPGMYRmeGWwZHXueEB1emGwc3PybZB1cW:wYXygZYN1cX[rdIm=NV3zVHByOjR3Mke3PVI>
DLD1MXjDfZRwfG:6aXOgRZN{[Xl?M4Lk[lIxKM7:TR?=MWexNEBlM3zZbWROW09?MnfkR5l1d3SxeHnjbZR6KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wMYeyOFUzPzd7Mh?=
VERONW\KN21LTnWwY4Tpc44hSXO|YYm=MXuyOUDPxE1?M2nNN2ROW09?NYrDdnpZTGm|dIXyZoV{KFCDUjDi[Yx1KHO7boTo[ZNqeyxiYX\m[YN1cW6pIITo[UBi[3SrbjDjfZRwe2unbHX0c44tKGOnbHygd4hieGViYX7kJINmdGxiYXTo[ZNqd25?NF2zbowzPTN|Mki0OS=>
HeLaMnXsSpVv[3Srb36gRZN{[Xl?MXOxNEDPxE1?M2PnNFQ5KGh?MmnPVoVlfWO2aX;uJI9nKGO7dH;wcIF{dWmlIHTpd5RzcWK3dHnvckBidmRiboXjcIVieiC2cnHud4xw[2G2aX;uJI9nKM7{LXPheIVvcW5?MYCyOVA3OTR7OR?=
SiHaMYDGeY5kfGmxbjDBd5NigQ>?M{XIfFExKM7:TR?=NU[4TW97PDhiaB?=NI\JVotT\WS3Y4Tpc44hd2ZiY4n0c5Bt[XOvaXOg[Il{fHKrYoX0bY9vKGGwZDDueYNt\WG{IITyZY5{dG:lYYTpc44hd2ZizsKtZ4F1\W6rbh?=MWKyOVA3OTR7OR?=

... Click to View More Cell Line Experimental Data

In vivo
Features

Protocol(Only for Reference)

Cell Assay: [1]

Cell lines WTK1 lymphoblasts
Concentrations 1.0 μM
Incubation Time 8 hours
Method XAV-939 is solubilized in DMSO at 55 °C to make a 10 mM stock solution which may be diluted later to a working concentration of 100 μM. WTK1 lymphoblasts treated with either DMSO or 1.0 μM XAV-939 for 8 hours are loaded into independent wells of a 4-20% gradient SDS-PAGE every 2 hours over the course of 6 hours. At each time point, DMSO and XAV-939 samples are loaded into wells immediately adjacent to the prior time point. The corresponding load times at 0, 2 and 4 hours results in total run times of 2, 4 and 6 hours respectively. The gel is analyzed via western blot for DNA-PKcs following completion of the final run time and is quantified after normalization to actin loading controls.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Dregalla RC, et al. Aging, 2010, 2(10), 691-708.

[2] Huang SM, et al. Nature, 2009, 461(7264), 614-620.

Chemical Information

Download XAV-939 SDF
Molecular Weight (MW) 312.31
Formula

C14H11F3N2OS

CAS No. 284028-89-3
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms NVP-XAV939
Solubility (25°C) * In vitro DMSO 12 mg/mL (38.42 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2-(4-(trifluoromethyl)phenyl)-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-4-ol

Customer Product Validation (5)


Click to enlarge
Rating
Source Nat Commun 2014 5, 5455. XAV-939 purchased from Selleck
Method Immunostaining
Cell Lines P19 cells
Concentrations 4 uM
Incubation Time 72 h
Results P19 cells transfected with expression vectors for the control or ​Cdo-shRNA with Top-flash and β-galactosidase were treated with either ​dimethylsuphoxide (​DMSO) or ​XAV939 (4 uM) in differentiation medium for 24 h. ​P19/control or P19/​Cdo shRNA cells were treated with ​DMSO or ​XAV939 in the differentiation medium for 72 h followed by immunostaining. XAV939-treated control cells displayed a modest increase in ​β-tubulin III-positive cells, compared with the control-treated cells. Furthermore, ​Cdo-depleted P19 cells treated with ​DMSO exhibited a significant reduction in ​β-tubulin III-positive cells, while ​XAV939 treatment restored neuronal differentiation of these cells nearly to the control level.

Click to enlarge
Rating
Source Dis Model Mech 2014 7(10), 1193-203. XAV-939 purchased from Selleck
Method Immunostaining
Cell Lines TH+ cells
Concentrations
Incubation Time 72 h
Results XAV-nano increased total cell number, the percentage of TH+ cells was reduced. This is illustrated in Figure.

Click to enlarge
Rating
Source Dr. Marco Quarta of Stanford University. XAV-939 purchased from Selleck
Method
Cell Lines
Concentrations 1-100 μM
Incubation Time
Results

Click to enlarge
Rating
Source XAV-939 purchased from Selleck
Method Sectional Immunohistochemistry
Cell Lines E14.5 male UGSs
Concentrations 10 μM
Incubation Time 4 d
Results Total bud numbers were compared among vehicle9 (control), TCDD9 (1 nM), DKK1 + DKK29 (500 ng/ml each), and XAV-939-(10 μM) treated UGSs by staining the UGE for e-cadherin and counting prostatic buds. All treatments decreased the total number of prostatic buds compared to control UGSs (p<0.05, Fig. 1, bottom). A confocal image that is representative of the UGS for each treatment is also shown (Fig. 1, top).

Click to enlarge
Rating
Source XAV-939 purchased from Selleck
Method Sectional Immunohistochemistry
Cell Lines E14.5 male UGSs
Concentrations 10 μM
Incubation Time 4 d
Results Cell elongation index measured from spindle-like morphology was used to determine the effect of individual inhibitors. Prevention of MSP-induced spindle-like morphology was not observed in M-RON cells treated with wortmannin, SB203580, SP600125, Cay10512, and S31-201, suggesting that signaling from these pathways was not involved in MSP-induced EMT. A moderate effect, based on changes in elongation index, was seen when rapamycin, vismodegib, and XAV-939 were applied, suggesting that signaling from Hedgehog, Wnt /b-catenin, and FRAP/mTOR pathways played a role in MSP-induced EMT.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Wnt/beta-catenin Products

  • ICG-001

    ICG-001 antagonizes Wnt/β-catenin/TCF-mediated transcription and specifically binds to element-binding protein (CBP) with IC50 of 3 μM, but is not the related transcriptional coactivator p300.

  • Wnt-C59 (C59)

    Wnt-C59 (C59) is a PORCN inhibitor for Wnt3A-mediated activation of a multimerized TCF-binding site driving luciferase with IC50 of 74 pM in HEK293 cells.

  • IWP-2

    IWP-2 is an inhibitor of Wnt processing and secretion with IC50 of 27 nM in a cell-free assay, selective blockage of Porcn-mediated Wnt palmitoylation, does not affect Wnt/β-catenin in general and displays no effect against Wnt-stimulated cellular responses.

  • IWR-1-endo

    IWR-1-endo is a Wnt pathway inhibitor with IC50 of 180 nM in L-cells expressing Wnt3A, induces Axin2 protein levels and promotes β-catenin phosphorylation by stabilizing Axin-scaffolded destruction complexes.

  • LGK-974

    LGK-974 is a potent and specific PORCN inhibitor, and inhibits Wnt signaling with IC50 of 0.4 nM in TM3 cells. Phase 1.

  • KY02111

    KY02111 promotes differentiation of hPSCs to cardiomyocytes by inhibiting Wnt signaling, may act downstream of APC and GSK3β.

    Features:May act downstream of APC and GSK3β in the canonical WNT signaling pathway.

  • FH535

    FH535 is a Wnt/β-catenin signaling inhibitor and also a dual PPARγ and PPARδ antagonist.

Recently Viewed Items

Tags: buy XAV-939 | XAV-939 supplier | purchase XAV-939 | XAV-939 cost | XAV-939 manufacturer | order XAV-939 | XAV-939 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us